Reimbursement deliberations for Camzyos, a new drug for obstructive hypertrophic cardiomyopathy (oHCM) that had received a redeliberation decision in the past, will again commence today.

According to industry sources, BMS Korea's obstructive hypertrophic cardiomyopathy (oHCM) drug Camzyos (mavacamten) will be presented to the latest Drug Reimbursement Evaluation Committee of the National Health Insurance Review and Assessment Service on the 4th.

Therefore, whether Camzyos will be deemed adequate for reimbursement and move on to the drug price negotiation stage with the National Health Insurance Service remains to be seen.

After passing the Economic Evaluation Subcommittee,